Pancreatic Cancer Research

ResearcherUniversity of OuluNo recent work listed

Kirsi‐Maria Haapasaari

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0009-9740-9876; OpenAlex author ID A5109104619. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
10
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers

Papers 10

  1. Immune cell score in pancreatic cancer-comparison of hotspot and whole-section techniques. Co-author DOI 10.1007/s00428-019-02549-1↗
  2. Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001195↗
  3. Expression Levels of microRNAs miR-93 and miR-200a in Pancreatic Adenocarcinoma with Special Reference to Differentiation and Relapse-Free Survival. Last author DOI 10.1159/000494274↗
  4. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. First author DOI 10.1016/j.prp.2018.04.016↗
  5. Weak HIF-1alpha expression indicates poor prognosis in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-018-1432-4↗
  6. KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma. First author DOI 10.21873/anticanres.12474↗
  7. High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients. Co-author DOI 10.1007/s00428-017-2087-1↗
  8. Loss of Peroxiredoxin Expression Is Associated with an Aggressive Phenotype in Pancreatic Adenocarcinoma. First author PMID 26722077↗
  9. Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma. Co-author DOI 10.1007/s13277-013-1503-7↗
  10. Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.prp.2013.10.001↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Peeter Karihtala · 7 shared papers, 2014–2019 · strength 0.61
  2. Joel Isohookana · 6 shared papers, 2016–2019 · strength 0.55
  3. Ylermi Soini · 6 shared papers, 2014–2019 · strength 0.52
  4. Joni Leppänen · 5 shared papers, 2017–2019 · strength 0.44
  5. Tuomo J. Karttunen · 4 shared papers, 2017–2019 · strength 0.33
  6. Joonas H. Kauppila · 3 shared papers, 2017–2019 · strength 0.24
  7. Heikki I. Huhta · 3 shared papers, 2017–2019 · strength 0.24
  8. Ilmo Kellokumpu · 1 shared paper, 2019 · strength 0.10
  9. Jan Böhm · 1 shared paper, 2019 · strength 0.10
  10. Kyösti Tahkola · 1 shared paper, 2019 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.